Evidera

Our CorEvitas, LLC team has launched a new registry, filling a critical gap for our customers and the broader research community, particularly as newer therapies and treatment paradigms are prescribed to treat Systemic Lupus Erythematosus (SLE). Learn more ⬇️

Our CorEvitas, LLC team has launched a new registry, which will assist the research community in contextualizing the effectiveness and safety of newly approved treatments for adolescents with alopecia areata (AA). Learn more ⬇️

The new era of #HTA in the EU is here! The new EU HTA Regulation (EU) 2021/2282 has begun for advanced therapeutics and oncology assets and will be fully implemented by 2030. Download this informative Insights Report, designed to help you navigate the path ahead. 💡 Gain insights into: • Overcoming challenges in Joint Clinical Assessment (JCA) submissions • Optimizing evidence planning with Joint Scientific Consultations (JSCs) • Mastering the Population, Intervention, Comparator(s), Outcomes (PICO) framework • Building organizational readiness • Collaborating across functions for seamless execution Learn more » https://bit.ly/42VoiCD #healthtechnologyassessment #realworldevidence #RWE

Heading to #SCOPEsummit? Be sure to attend our panel discussion, where Stephanie Terrey, senior director, patient insights research, joins our PPD colleagues to demonstrate how applying the right data strategies can design truly patient-centered trial experience.   📅 Tuesday, Feb. 4 at 1:05 p.m. ET   Can’t make the panel discussion? Visit us at booth 817. Learn more about our patient-centered solutions or request a meeting. » https://bit.ly/4hkOfzm

Is your vaccine development program leveraging the full potential of RWE? 💉 Our latest white paper explores how #RWE can: ➡️ Accelerate clinical trial timelines ➡️ Strengthen regulatory submissions ➡️ Enhance market access and uptake 👉 Read more about our team's new initiative to help accelerate #vaccine market access timelines. » https://bit.ly/42pRi58

Our team was delighted to have been part of #ISPOREurope 2024! Thank you ISPOR—The Professional Society for Health Economics and Outcomes Research for the opportunity to share groundbreaking research and engage in forward-thinking discussions with brilliant minds in the health research community. 🏅 We are thrilled to share that four of our posters were recognized as ISPOR Top 5% Award finalists! Congratulations to the presenters Phillip Leventhal, LALITH KUMAR MITTAL, Simone Rivolo and Naomi Stapleton, and everyone who contributed to this impactful research. Unable to attend? Want to continue the discussion? Contact us 📨 https://bit.ly/3ZUXUqr0

📅 Join us on Thursday, Dec. 5, for a webinar on the implications of the Inflation Reduction Act on pricing negotiations for your product portfolio. Gain valuable insights from our experts Haripriya Jain, Ariel Berger and Sarah Ronnebaum as they offer perspectives around evidence strategies to help manufacturers demonstrate product value for #Medicare price negotiations. Register now! » https://bit.ly/4hLHSG8 #IRA #InflationReductionAct #DrugPricing #MaximumFairPrice #MFP

Join us at #ISPOREurope in Barcelona on Nov. 17-20! Connect with our experts to explore how our expertise in #RWD, #RWE, market access and patient engagement strategies can drive innovation in #HEOR. 📅 Schedule a meeting. » https://bit.ly/3YsORuX

Attending the DIA Real-World Evidence Conference? Don't miss Delphine Saragoussi, MD, MScPH , executive director, epidemiology and scientific affairs, as she speaks on test-negative design studies during session 7 on Friday, Oct. 25. Learn more about our work. » https://bit.ly/3pSoAZo #rwe #epidemiology

Meet us at #WVCEU! Our team is eager to discuss your unique challenges. Discover how leveraging #realworlddata, #realworldevidence and our global resources can unlock the full potential of your vaccine program. Visit us at booth 69 or attend our Working Group on Wednesday, Oct. 30 with Delphine Saragoussi, MD, MScPH , Sarah Rosen, Javier Cid and Narcisa MESAROS, MD. » https://bit.ly/3BTJRrK